Transforaminal vs. Interlaminar Injections: Key Differences

Transforaminal and interlaminar epidural steroid injections both deliver corticosteroid medication into the epidural space around the spinal cord, but they take fundamentally different paths to get there and are suited to different clinical situations. The transforaminal approach threads a needle alongside a nerve root as it exits the spine, targeting a single level with precision. The interlaminar approach enters from the back of the spine, between two vertebral arches, depositing medication more broadly across the epidural space. That difference in needle path shapes nearly everything that follows: how well each works for particular diagnoses, what risks each carries, and which one your doctor is likely to recommend.

How Each Approach Reaches the Epidural Space

The epidural space is a thin corridor that wraps around the spinal cord and nerve roots, cushioned by fat and blood vessels. Both injections aim to place anti-inflammatory steroid into this corridor, but they arrive from opposite directions. The interlaminar approach enters from the posterior (back) side of the spine, passing between two laminae, the bony plates that form the rear wall of the spinal canal. The needle slides through the ligamentum flavum, a tough ligament that lines the back of the canal, and deposits medication into the posterior epidural space. Because the needle enters centrally, the steroid tends to spread across multiple levels and both sides of the spine.

The transforaminal approach enters from the side, through the neural foramen, which is the small opening where a spinal nerve root exits the vertebral column. The needle is guided to the anterior (front) portion of the epidural space, right alongside the targeted nerve root. This lets the physician place a concentrated dose of steroid directly where a herniated disc or bone spur is irritating the nerve. Because of this precision, transforaminal injections typically require a smaller total volume of medication to achieve their effect.

Both procedures are performed under fluoroscopic (live X-ray) guidance, with contrast dye injected first to confirm the needle’s position before any steroid is delivered. The contrast also shows the physician how the medication will spread, which matters because the spread pattern differs between approaches. A study comparing contrast flow found that parasagittal interlaminar injections achieved anterior epidural spread in all patients, while transforaminal injections achieved anterior spread in about three-quarters of cases, though the transforaminal approach concentrated that spread closer to the affected nerve root.¹

Efficacy for Lumbar Leg Pain and Radiculopathy

The most common reason people get either injection is radiculopathy: pain, tingling, or weakness that shoots down the leg because a nerve root in the lower back is compressed or inflamed. The evidence on which approach works better for this is genuinely mixed, with studies pointing in different directions depending on how they measure success and how long they follow patients.

A registry-based study that combined patients with radicular pain and neurogenic claudication into a single “leg pain” group found that roughly 57% of those who received transforaminal injections achieved at least a 50% reduction in leg pain, compared to 30% in the interlaminar group. After adjusting for steroid type and the nature of presenting symptoms, transforaminal injections were associated with about 3.6 times the odds of achieving that level of pain relief.² That is a meaningful difference favoring the transforaminal route, at least for leg-dominant symptoms.

Other studies, however, show no significant difference. One trial tracking patients at one, three, and six months found comparable improvements in pain scores, functional disability scores, and overall outcomes between the two approaches over time.³ Similarly, a comparison of transforaminal and parasagittal interlaminar injections found that both produced significant pain and disability improvements at two weeks, with no meaningful difference between groups.⁴

One way to reconcile these findings: the transforaminal approach appears to shine most when the problem is clearly one-sided and nerve-specific, like a single-level disc herniation pressing on one nerve root. A comprehensive review noted that transforaminal injections are especially useful for unilateral radiculopathy, focal disc herniation, or foraminal stenosis because the medication reaches the target with less dilution.⁵ When the pain is more diffuse or bilateral, the broader spread of an interlaminar injection can be equally effective.

For back-dominant pain rather than leg pain, neither approach has a clear edge. In the same registry study mentioned above, about 31% of transforaminal patients and 35% of interlaminar patients achieved at least a 50% reduction in back pain, a statistically negligible difference.² This makes sense: back pain often comes from structures that neither injection targets as directly as an inflamed nerve root.

When the Diagnosis Is Spinal Stenosis

Lumbar spinal stenosis, where the spinal canal itself narrows and compresses multiple nerve roots, presents a different challenge. The pain often involves both legs and worsens with walking, unlike the sharp, one-sided shooting pain of radiculopathy. You might expect the interlaminar approach’s broader spread to be advantageous here, but the evidence is not that simple.

A comparative study of three epidural approaches in stenosis patients found that transforaminal injections produced lower pain scores and better treatment outcomes starting one month after injection and persisting through follow-up, outperforming both interlaminar and caudal approaches.⁶ However, another study that specifically compared transforaminal and interlaminar injections for stenosis found no difference in short-term pain improvement, and no difference in the rates of subsequent surgery or repeat injections.⁷

In practice, when stenosis is the primary issue, the choice between approaches often comes down to anatomy. Some patients with severe stenosis have such a narrow spinal canal that an interlaminar approach carries a higher risk of accidentally advancing the needle too far. In those cases, a transforaminal approach, which bypasses the central canal entirely, can be the safer route even if the clinical outcome is similar.

The Cervical Spine Changes the Calculus

Everything discussed so far has focused on the lumbar (lower back) spine, and the comparison shifts when you move up to the cervical (neck) region. In the cervical spine, the risks of a transforaminal injection become more pronounced because the vertebral artery and critical radicular arteries are in closer proximity to the needle path. This makes cervical transforaminal injections higher-stakes from a safety standpoint.

Interestingly, the efficacy comparison also tilts toward the interlaminar approach in the neck. A retrospective analysis of cervical epidural steroid injections found that interlaminar injections had a 59% success rate for achieving at least 50% pain relief, compared to 46% for transforaminal injections. When the bar was raised to 80% pain relief, the gap widened: 37% for interlaminar versus 17% for transforaminal, a statistically significant difference.⁸

A randomized trial comparing the two cervical approaches found broadly similar functional outcomes at one and three months, though it noted one key safety observation: nearly one in five transforaminal injections showed vascular uptake of contrast dye, meaning the needle was dangerously close to or inside a blood vessel.⁹ No serious complications occurred in that trial, but the vascular visualization rate illustrates why many pain specialists favor the interlaminar route for cervical injections. The authors concluded that parasagittal interlaminar injection may be preferable in the cervical spine when both safety and effectiveness are weighed together.

Safety and the Vascular Risk of Transforaminal Injections

The most serious complication unique to transforaminal injections is inadvertent injection into an artery that feeds the spinal cord. A small artery called the artery of Adamkiewicz, or one of its feeders, can sometimes run through the neural foramen right where the transforaminal needle is positioned. If steroid particles are injected into this vessel, they can travel upstream and block blood flow to the spinal cord, causing ischemia or infarction. Case reports have documented spinal cord infarction following lumbar transforaminal injections, where angiography revealed occlusion of a segmental artery, presumably from the steroid itself blocking the vessel.¹⁰

This complication is rare but catastrophic when it occurs, and it has shaped procedural technique in significant ways. The traditional “supraneural” needle placement, where the needle sits above the exiting nerve root, puts it closer to the arterial territory. A newer “infraneural” approach positions the needle below the nerve root, where critical arteries are less likely to be encountered. As one review explains, the concern is not simply intravascular uptake into any vessel, but specifically injection into a radicular or radiculomedullary artery supplying the spinal cord, where embolic occlusion could result in spinal cord ischemia.¹¹

Interlaminar injections carry their own risks, primarily dural puncture (where the needle goes too deep and pierces the membrane surrounding the spinal cord fluid) and the fact that the posterior approach places the needle closer to the spinal cord itself in the cervical and thoracic regions. But the specific risk of arterial embolism that haunts the transforaminal approach is largely absent from the interlaminar technique, which is one reason many practitioners default to interlaminar injections in the cervical spine.

Particulate Versus Non-Particulate Steroids

The vascular risk of transforaminal injections is tightly linked to the type of steroid used. Particulate steroids like triamcinolone and methylprednisolone form small clumps that can physically block blood vessels if injected intra-arterially. Non-particulate steroids like dexamethasone dissolve fully in solution, so even if they inadvertently enter a blood vessel, they are far less likely to cause an embolic event.

This safety concern has pushed many practitioners toward using non-particulate steroids for transforaminal injections, especially at higher-risk spinal levels. A survey of physician perceptions found that non-particulate steroids are generally favored in higher-risk injections because of their safety profile. The same analysis noted that existing evidence suggests outcomes between particulate and non-particulate steroids are often comparable, while the rare but potentially catastrophic neurologic complications remain an important concern with particulate steroid use in transforaminal settings.¹²

The picture is not quite as clean as “always use non-particulate for transforaminal.” A review of the evidence noted that spinal cord infarction has been reported with both particulate and non-particulate steroids during transforaminal injections, and database analyses have found no clear difference in complication rates between the two. There is also some evidence that particulate steroids may provide longer-lasting relief, potentially reducing the total number of injections a patient needs.¹³ Steroid selection remains an area of individual clinical judgment, where physicians weigh the potential for longer-lasting benefit against the small but severe risk of embolic injury.

For interlaminar injections, this debate is less urgent. Because the needle enters posteriorly and is not positioned near radicular arteries, the risk of intra-arterial injection is substantially lower, and particulate steroids are generally used without the same level of concern.

The Diagnostic Role of Transforaminal Injections

Beyond pain relief, transforaminal injections serve a purpose that interlaminar injections cannot easily replicate: diagnostic confirmation. When imaging shows abnormalities at multiple spinal levels and the physician is not certain which one is causing the patient’s symptoms, a transforaminal injection at a single nerve root functions as a selective nerve root block. If the patient’s pain dramatically improves after a specific level is targeted, that level is confirmed as the symptomatic source. This information becomes valuable in surgical planning if the patient eventually needs an operation, because it can help the surgeon limit the procedure to the relevant level rather than performing a broader fusion.⁵

An interlaminar injection, by contrast, bathes multiple levels and both sides of the epidural space in steroid and anesthetic. If a patient feels better afterward, you know something in that general region was inflamed, but you have not isolated which nerve root was responsible. For pure symptom relief, that ambiguity may not matter. For planning a surgical decompression or deciding between a conservative and operative path, it can matter a great deal.

Detecting Intravascular Needle Placement

Because the vascular risk of transforaminal injections is the most feared complication, imaging techniques for detecting accidental blood vessel entry have been studied closely. The two main options are real-time fluoroscopy, where the physician watches the contrast dye flow live under X-ray, and digital subtraction angiography, which digitally removes bone and soft tissue from the image to make blood vessels stand out more clearly. You might assume the more sophisticated technology would catch more problems, but a comparison of the two methods during cervical transforaminal injections found similar detection rates: intravascular injection was identified in about 31% of cases with real-time fluoroscopy and 34% with digital subtraction angiography, with no statistically significant difference.¹⁴

The rates themselves are striking: roughly a third of cervical transforaminal injections showed some degree of vascular uptake. In the vast majority of these cases, the physician detects it on the contrast run and repositions the needle before injecting steroid, which is exactly why contrast confirmation is standard practice. But the frequency underscores why cervical transforaminal injections demand meticulous technique and why some guidelines recommend the interlaminar route when the clinical situation allows it.

Radiation Exposure Differences

Both injection types require fluoroscopy, but they do not use the same amount of radiation. An observational study measuring radiation doses across different epidural approaches found that lumbar transforaminal injections involved a lower dose per procedure than lumbar interlaminar injections. Procedure times were also shorter for transforaminal injections, averaging about 37 seconds of fluoroscopy time compared to roughly 47 seconds for interlaminar injections.¹⁵ The absolute doses involved in either approach are low enough that a single injection is not a meaningful health concern, but the difference becomes relevant for patients who undergo repeated injections over months or years. Someone receiving a series of three or four lumbar injections annually may accumulate meaningfully different total exposure depending on the approach used, and every bit of radiation avoided is a reasonable goal.

The shorter fluoroscopy time for transforaminal injections may seem counterintuitive, since the needle path is more technically demanding. But the transforaminal approach typically uses a single oblique view to guide the needle to a well-defined bony landmark, the so-called “Scotty dog” view of the vertebra. The interlaminar approach often requires the physician to switch between anteroposterior and lateral views to gauge needle depth as it passes through the ligamentum flavum, which adds screening time. In cervical interlaminar injections, the radiation dose dropped to the lowest of any approach studied, likely because the neck is thinner and requires less X-ray energy to image.